Back to Multi-Omics Hub

Kinomics Platform

Comprehensive kinase activity profiling for precision oncology and targeted therapy selection

Human Kinases

518

Kinase Inhibitors

75+ FDA

Phospho-sites

100,000+

Clinical Trials

3,500+

Kinomics: Mapping the Kinase Universe

Kinomics comprehensively profiles the activity of the 518 human protein kinases that phosphorylate proteins to control virtually all cellular processes. Kinase dysregulation drives cancer, inflammation, and metabolic diseases. Over 75 kinase inhibitors are FDA-approved, with 518 kinases representing the largest drug target class.

Technology Platforms

  • Phosphoproteomics: MS-based phosphorylation site mapping
  • Kinase Activity Arrays: Peptide substrate phosphorylation
  • Chemical Proteomics: Kinase inhibitor binding profiling
  • CRISPR Screens: Functional kinase dependency mapping

Key Applications

  • Precision Oncology: Guide selection of 75+ FDA-approved kinase inhibitors
  • Drug Resistance: Identify bypass signaling and resistance mutations
  • Drug Discovery: Target validation and kinase inhibitor profiling
  • Biomarker Development: Phospho-protein diagnostic assays

Kinomics Workflow

1

Sample Prep

Tumor, blood, cells - phosphatase inhibitors

2

Phospho-enrichment

TiO2, IMAC, antibody enrichment

3

MS Analysis

LC-MS/MS phosphoproteomics

4

Kinase Inference

Substrate-to-kinase mapping, KSEA

75+ FDA-Approved TKIs

Kinase inhibitors are the largest class of targeted cancer therapies, with more in clinical development

AI Kinase Activity Inference

Machine learning predicts kinase activity from phosphoproteomics data using KSEA and PhosphoSitePlus

Clinical Implementation

Companion diagnostics for EGFR, ALK, BRAF guide >$50B annual kinase inhibitor market